Who is the CEO of Advaxis, Inc.?

Mr. Kenneth A. Berlin J.D. is a business executive who currently serves as the CEO of Advaxis, Inc..

What is the Revenue Growth of Advaxis, Inc.?

Revenue growth data for Advaxis, Inc. is currently unavailable.

What is Advaxis, Inc. operating Margin?

Advaxis, Inc. operating margin is -278969.23% which shows how much profit ADXS earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Advaxis, Inc. operate?

Advaxis, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Advaxis, Inc. revenue growth?

Revenue growth data for Advaxis, Inc. is currently unavailable.

Advaxis, Inc.

ADXS•PNK

HealthcareBiotechnology

$0.04

$0.003(9.81%)

Advaxis, Inc. (ADXS) Stock Overview

Explore Advaxis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ADXSStats details for ADXS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for ADXSAnalyst Recommendations details for ADXS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

CEO

Mr. Kenneth A. Berlin J.D.

Employees

Headquarters

9 Deer Park Drive, Monmouth Junction, NJ

Founded

2020